[HTML] nature.com

[HTML][HTML] COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

…, D Maurus, S Brachtendorf, V Lörks, J Sikorski… - Nature, 2020 - nature.com
An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and …
Save Cite Cited by 1850 Related articles All 16 versions
[HTML] nature.com

[HTML][HTML] BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

…, D Maurus, S Brachtendorf, V Lörks, J Sikorski… - Nature, 2021 - nature.com
BNT162b2, a nucleoside-modified mRNA formulated in lipid nanoparticles that encodes the
SARS-CoV-2 spike glycoprotein (S) stabilized in its prefusion conformation, has …
Save Cite Cited by 631 Related articles All 12 versions

An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma

…, A Hohberger, I Vogler, I Liebig, S Renken, J Sikorski… - Nature, 2020 - nature.com
Treating patients who have cancer with vaccines that stimulate a targeted immune response
is conceptually appealing, but cancer vaccine trials have not been successful in late-stage …
Save Cite Cited by 638 Related articles All 9 versions
[PDF] medrxiv.org

BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans

…, D Maurus, S Brachtendorf, V Lörks, J Sikorski… - MedRxiv, 2020 - medrxiv.org
BNT162b2, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA (mRNA)
encoding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike …
Save Cite Cited by 183 Related articles All 7 versions Cached
[PDF] medrxiv.org

Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine

…, D Maurus, S Brachtendorf, V Lörks, J Sikorski… - MedRxiv, 2020 - medrxiv.org
An effective vaccine is needed to halt the spread of the SARS-CoV-2 pandemic. Recently,
we reported safety, tolerability and antibody response data from an ongoing placebo-…
Save Cite Cited by 83 Related articles All 6 versions Cached

Designed cell consortia as fragrance-programmable analog-to-digital converters

…, A Spinnler, D Ausländer, J Sikorski… - Nature chemical …, 2017 - nature.com
Synthetic biology advances the rational engineering of mammalian cells to achieve cell-based
therapy goals. Synthetic gene networks have nearly reached the complexity of digital …
Save Cite Cited by 57 Related articles All 6 versions

Publisher correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

…, D Maurus, S Brachtendorf, V Lörks, J Sikorski… - …, 2021 - pubmed.ncbi.nlm.nih.gov
… 3 , Julian Sikorski …
Save Cite Cited by 32 Related articles All 10 versions

A shared tumor-antigen RNA-lipoplex vaccine with/without anti-PD1 in patients with checkpoint-inhibition experienced melanoma.

…, S Attig, K Cuk, I Vogler, J Sikorski… - 2020 - ascopubs.org
3136 Background: Cancer vaccines are considered unsuitable for patients with advanced
tumours and have not been clinically successful. Methods: Lipo-MERIT is an ongoing phase 1/…
Save Cite Cited by 15 Related articles
[PDF] lodz.pl

[PDF][PDF] Aqueous solutions of hydrochloric acid as simple solvents of chitosan for viscosity-and light-scattering-based molecular weight determination

…, A Wojtasz-Pająk, J Sikorski… - Polish Chitin …, 2007 - ptchit.lodz.pl
Basic studies on chitosan and practical applications of this biopolymer require knowledge of
its major physicochemical properties, especially the molecular weight and degree of …
Save Cite Cited by 12 Related articles All 2 versions View as HTML

549 An RNA-lipoplex (RNA-LPX) vaccine demonstrates strong immunogenicity and promising clinical activity in a Phase I trial in cutaneous melanoma patients with …

…, P Brück, E Derhovanessian, K Cuk, V Lörks, J Sikorski… - 2021 - jitc.bmj.com
Background Lipo-MERIT is an ongoing, first-in-human, open-label, dose-escalation Phase I
trial investigating safety, tolerability and immunogenicity of BNT111 in patients with …
Save Cite Cited by 2 Related articles